Cargando…
Integrated human/SARS-CoV-2 metabolic models present novel treatment strategies against COVID-19
The coronavirus disease 2019 (COVID-19) pandemic caused by the new coronavirus (SARS-CoV-2) is currently responsible for more than 3 million deaths in 219 countries across the world and with more than 140 million cases. The absence of FDA-approved drugs against SARS-CoV-2 has highlighted an urgent n...
Autores principales: | Bannerman, Bridget P, Júlvez, Jorge, Oarga, Alexandru, Blundell, Tom L, Moreno, Pablo, Floto, R Andres |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Life Science Alliance LLC
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8343166/ https://www.ncbi.nlm.nih.gov/pubmed/34353886 http://dx.doi.org/10.26508/lsa.202000954 |
Ejemplares similares
-
Mycobacterial metabolic model development for drug target identification
por: Bannerman, Bridget P., et al.
Publicado: (2023) -
CONTRABASS: exploiting flux constraints in genome-scale models for the detection of vulnerabilities
por: Oarga, Alexandru, et al.
Publicado: (2023) -
Mabellini: a genome-wide database for understanding the structural proteome and evaluating prospective antimicrobial targets of the emerging pathogen Mycobacterium abscessus
por: Skwark, Marcin J, et al.
Publicado: (2019) -
Using Structure-guided Fragment-Based Drug Discovery to Target Pseudomonas aeruginosa Infections in Cystic Fibrosis
por: Arif, Sheikh Mohammed, et al.
Publicado: (2022) -
SARS-CoV-2 3D database: understanding the coronavirus proteome and evaluating possible drug targets
por: Alsulami, Ali F, et al.
Publicado: (2021)